Phase 1 · NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
- ClinicalTrials.gov ID
- NCT05611957
- Indication
- Healthy, Renal Insufficiency
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 29
- Status
- Completed
- Interventions
- Drug: LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 85 Years
- Locations
- 4 sites · United States
- Study start
- 16 Nov 2022
- Primary completion
- 5 Sept 2023
- Study completion
- 5 Sept 2023
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 2 Oct 2023
Endpoints
Primary
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943; PK: Maximum observed concentration (Cmax) of LY3437943